WO2006056038A1 - Pyridoxal-5-phosphate and stent for the treatment and prevention of atherosclerosis and restenosis - Google Patents
Pyridoxal-5-phosphate and stent for the treatment and prevention of atherosclerosis and restenosis Download PDFInfo
- Publication number
- WO2006056038A1 WO2006056038A1 PCT/CA2005/001471 CA2005001471W WO2006056038A1 WO 2006056038 A1 WO2006056038 A1 WO 2006056038A1 CA 2005001471 W CA2005001471 W CA 2005001471W WO 2006056038 A1 WO2006056038 A1 WO 2006056038A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phosphate
- pyridoxal
- pharmaceutically acceptable
- acceptable salt
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
Definitions
- Pyridoxal-5-phosphate and stent for the treatment and prevention of atherosclerosis and restenosis.
- the present invention relates to compounds and methods for treating and preventing atherosclerosis and restenosis.
- Atherogenesis has long been considered to consist primarily of cholesterol build-up in the arteries. While high plasma . concentrations of cholesterol (in particular, low density lipoprotein, or LDL) constitute one of the principal risk factors for the disease (1), atherogenesis is now understood to be a much more complex process. Indeed, despite widespread use of lipid-iowering agents such as statins, cardiovascular disease remains the leading cause of death in Canada, the United States, and the rest of the world (2). It has become clear that, in devising new strategies to treat this disease, it is necessary to look beyond cholesterol. Atherosclerosis is now known to be a multifactorial disease.
- Percutaneous transluminal coronary angioplasty is the most commonly employed revascularization procedure for treating coronary artery disease including atherosclerosis.
- the long-term success of angioplasty is limited by the occurrence of restenosis, which is. observed In 30-60% of . patients within 6 months (5). Patients experiencing restenosis must often undergo repeat revascularization procedures.
- the introduction of stents, in particular drug-eluting stents, has reduced the incidence of restenosis to 10- 30% (6) however, restenosis is still a significant problem at these rates of incidence.
- statins are also potent anti-inflammatory agents, they do not address the other numerous factors (including lipidoxidation, vascular cell proliferation, hyperhomocysteinemia and thrombosis) which contribute to the development and progression of atherosclerosis.
- combination therapies have been proposed comprising one or more of lipid lowering agents, anti-thrombosis agents, and/or homocysteine lowering agents.
- statins in combination with aspirin, beta-blockers, and angiotensin converting enzyme (ACE) inhibitors has been advocated for aggressive treatment of atherosclerosis (126).
- combination therapies comprising different classes of drugs allow for treatment of multiple risk factors
- the usefulness of such therapies may be limited due to adverse drug-drug interactions.
- the concurrent administration of multiple drugs may result in increased toxicity and/or decreased efficacy of one or more the drugs.
- one drug may negatively affect the metabolism of another co-administered drug.
- the statin, atorvastin has been shown to reduce the effectiveness of clopidogrel, an inhibitor of platelet aggregation (127). Atorvastin, a substrate for CYP3A4, competitively inhibits CYP3A4 activation of clopidogrel.
- combination therapies may also be limited due to poor patient compliance if the treatment regimen is overly complex, for example, if individual drugs have to be taken separately at different times of the day or if certain drugs have to taken on an empty stomach whereas the other drugs have to be taken on a full stomach. It is well established that increased treatment complexity is directly correlated with decreased patient compliance. Thus the effectiveness of a combination therapy is related not only to the pharmaceutical efficacy of the particular combination of the drugs, but also the ease and simplicity of carrying out the treatment
- Pyridoxal-5' ⁇ phosphate is a well known vitamin B6 compound.
- the present inventors have previously disclosed the usefulness of P5P for the treatment of cardiovascular diseases such as hypertrophy, hypertension, congestive heart failure, and ischemia (See US Patent No. 6,677,356).
- Apoptosis plays a key role in regulation of the integrity of the arterial wall. During atherogenesis, deregulated apoptosis may cause abnormalities of arterial morphogenesis, wall structural stability, and metabolisms. Many biophysiologic and biochemical factors, including mechanical forces, reactive oxygen and nitrogen species, cytokines, growth factors, oxidized lipoproteins, etc. may induce or influence apoptosis of vascular cells. Apoptosis also plays a significant role in plaque destabilization. Macrophages are the most predominant cell type in atherosclerotic lesions. Recent reports have suggested that macrophage apoptosis promotes plaques destabilization in advanced atherosclerotic lesions.
- ATP adenosine triphosphate
- P5P inhibits the effects of extra-cellular ATP in a number of different tissue types including the heart (89, 90), vagus nerve (91), vas deferens (91) and smooth muscle cells (92).
- P5P inhibits ATP induced calcium influx in freshly isolated adult rat cardio myocytes (89, 93) and inhibits the positive inotropic effects of ATP on isolated perfused rat hearts (89, 90).
- the effects of P5P on the inhibition of apoptosis, or its ability to decrease the rate of restenosis following angioplasty, has never been contemplated and is not known.
- Inflammation is a key component of the atherogenic process, from the initiation of the fatty streak to the advanced, complicated lesion (3, 94, 95).
- the presence of oxidized LDL and other lipids in the subendothelial space can generate an inflammatory response, causing monocytes to adhere to the vessel wall.
- Monocytes are transformed into macrophages, which can take up oxidized LDL to form foam cells.
- these cells then also release cytokines and growth factors that stimulate vascular cell migration and proliferation (3, 94, 95). Platelets can also adhere to the damaged vessel wall.
- the platelets When activated, the platelets release their granules, which contain cytokines and growth factors that may also contribute to the migration and proliferation of vascular cells (3). Activation of platelets also leads to the formation of free arachidonic acid (3). Arachidonic acid can be converted into prostaglandins such as thromboxane A2 (a potent vasoconstrictor and platelet aggregator) or leukotrienes (which may contribute to the inflammatory response) (3). Activated platelets which are adherent to the vessel wall also recruit other platelets, leading to the formation of a thrombus, which may cause blockage of the artery (3). Both inflammation and thrombosis are crucial components of the atherogenic process. Therefore, both must be addressed in treating the disease.
- prostaglandins such as thromboxane A2 (a potent vasoconstrictor and platelet aggregator) or leukotrienes (which may contribute to the inflammatory response) (3).
- Activated platelets
- Interleukin-1 is an important inflammatory mediator produced in abundance by activated monocytes and macrophages (106).
- IL-I biological activity is derived from two related but distinct polypeptides, IL-l ⁇ and ' IL-l ⁇ (106, 107).
- Human IL-Ip is synthesized as a 31-kDa pro-cytokine that is incompetent to bind to the type 1 IL-I receptor (108).
- pro-IL- l ⁇ must be cleaved by caspase-1 to yield a 17 kDa carboxyl terminus-derived polypeptide (109, 110).
- IL-l ⁇ is released from monocytes and macrophages via an atypical secretory mechanism that does not involve the endoplasmic reticulum and Golgi complex (111). Release of IL-l ⁇ from cells stimulated to produce this cytokine is generally an inefficient process. The majority of newly synthesized cytokine molecules remains cell associated and/or are degraded (112-114). To promote the efficient proteolytic cleavage of pro-IL-l ⁇ and release of the 17 kDa mature peptide, the cytokine-producing cells must be treated with a secretion stimulus such as ATP (115-117).
- a secretion stimulus such as ATP
- Extra-cellular ATP markedly accelerates the rate of processing and release of IL- l ⁇ in both monocytes and macrophages that have been primed with lipopolysaccharrides (LPS) (116-118).
- LPS lipopolysaccharrides
- the ATP induced changes are mediated via the activation of P2X7 purinergic receptors (117, 119) which serve as nonselective cation channels, which facilitate the rapid influx of extra-cellular Na+ and Ca2+ and the efflux of intra-cellular K+.
- Prolonged or repeated stimulation of P2X7 receptors also results in the activation of nonselective pores that allow molecules ⁇ 800 Da to diffuse into and out of the cells (120).
- Thrombosis is also implicated in the development of atherosclerois.
- P5P has been reported to inhibit ADP, thrombin, adrenaline, platelet activating factor, and arachidonic acid-induced human platelet aggregation and 14C-5HT release In vitro (122).
- thromboxane B2 generation induced by all of these agents was also inhibited by P5P (122).
- the present invention provides a method of treating or preventing a condition selected from a group consisting of: vascular inflammation, atherosclerosis, restenosis, plaque destabilization, and bypass graft failure comprising administering to a patient in need thereof a therapeutically effective amount of pyridoxal-5'-phosphate or pharmaceutically acceptable salt thereof.
- the method of treating vascular inflammation, atherosclerosis, restenosis, plaque destabilization, and bypass graft failure further comprises administering a therapeutically effective amount of an anti-inflammatory agent or a cardioprotective agent.
- the present invention provides a method of treating atherosclerosis in a patient suffering thereof comprising the administration of a therapeutically effective amount of pyridoxal-5' ⁇ phosphate prior to the patient undergoing a percutaneous coronary intervention.
- the present invention provides a use of a therapeutically effective amount of pyridoxai-5'-phosphate or pharmaceutically acceptable salt thereof for the prevention or treatment of a condition selected from a group consisting of: vascular inflammation, atherosclerosis, restenosis, plaque destabilization and bypass failure.
- the present invention provides a use of pyrid ⁇ xal-5'-phos ⁇ hate or a pharmaceutically acceptable salt thereof for the preparation of a medicament useful for the prevention or treatment of a condition selected from a group consisting of: vascular inflammation, atherosclerosis, restenosis, plaque destabilization and bypass failure.
- the present Invention provides an intravascular stent for use with a narrowed artery wherein said stent has at least one surface which is reversibly bound with pyridoxal-5'-phosphate or a pharmaceutically acceptable salt thereof.
- the inventors also find that P5P is effective in slowing the progression of atherosclerosis in afflicted individuals,
- P5P is effective for reducing the incidence and severity of restenosis in individuals having undergone a surgical intervention for the treatment of atherosclerosis.
- the present invention provides the use of P5P or a pharmaceutically acceptable salt thereof for treating individuals at risk for developing atherosclerosis, individuals having atherosclerosis, individuals at risk for developing restenosis and individuals having restenosis.
- the present invention also provides the use of P5P or a pharmaceutically acceptable salt thereof for treating and preventing vascular inflammation, plaque destabilization and bypass graft failure caused by or relating to atherosclerosis and/or restenosis.
- the methods of treatment according to the present invention encompass the use of P5P for modulating multiple factors which contribute to the development and progression of atherosclerosis and restenosis.
- the present invention provides uses and methods of treatment which are safe, effective for ameiiorating multiple risk factors, conducive to patient compliance, and low cost.
- the methods of treating and preventing atherosclerosis according to the invention comprise the administration of a therapeutically effective amount of P5P to a patient in need thereof. Animal and human studies show that P5P is easily tolerated and has low toxicity.
- P5P treatment is effective for modulating the primary factors underlying the development and progression of atherosclerosis, namely, hypercholesterolemia, lipid oxidation, vascular cell proliferation, hyperhomocysteinemia, vascular cell apoptosis, inflammation, and thrombosis.
- P5P provides a simple alternative to currently available combination therapies which require the administration of multiple classes of drugs which are often quite costly.
- P5P As only one drug, namely P5P, needs to be administered, the ease of carrying out the methods of treatment according the invention is much greater as compared to prior art combination therapies and as such, the likelihood of patient compliance is greatly increased.
- P5P modulates multiple causative factors, fewer classes of drugs are required in order to address the equivalent number of risk factors addressed by current combination therapies.
- combination therapies comprising P5P have lower incidences of adverse drug-drug interactions.
- P5P advantageously modulates: (1) hypercholesterolemia and lipid oxidation, (2) vascular cell proliferation, (3) hyperhomocysteinemia, (4) vascular cell apoptosis, and (5) inflammation and thrombosis to provide substantial benefit, when administered, to individuals with or at risk of atherosclerosis and/or restenosis.
- Hypercholesterolemia and Lipid Oxidation advantageously modulates: (1) hypercholesterolemia and lipid oxidation, (2) vascular cell proliferation, (3) hyperhomocysteinemia, (4) vascular cell apoptosis, and (5) inflammation and thrombosis to provide substantial benefit, when administered, to individuals with or at risk of atherosclerosis and/or restenosis.
- the present inventors confirm the lipid modulating properties of P5P. Unexpectedly, the present inventors find that the lipid modulating properties of P5P are substantially more effective than those of pyridoxine or magnesium P5P glutamate. The present inventors further find that individuals treated with P5P show clinically significant alterations to their lipid profiles as compared to the profiles of individuals treated with placebo, including decreased LDL levels, increased HDL levels, and decreased levels of oxidized lipids. Furthermore, the inventors find that the P5P-modulated changes in lipid profile are correlated with a lowered incidence of the formation of plaque lesions.
- P5P appears to have much higher effectiveness than other vitamin B6 compounds tested, for modulating hypercholestrolemia and lipid oxidation, two known factors for atherosclerosis.
- the inventors also find that this modulation results in lower incidences of formation of plaque lesions, and hence would be effective in treatment of atherosclerosis and/or restenosis.
- the present inventors find that P5P effectively inhibits vascular cell proliferation.
- the inventors find that P5P inhibition of vascular cell proliferation is useful in the treatment of both pre-atherosclerotic individuals and individuals having advanced atherosclerosis.
- the inventors also find that the anti ⁇ proliferative properties of P5P in vivo are substantially greater than those of pyridoxine.
- the inventors surprisingly find that P5P is effective for inhibiting vascular cell proliferation in coronary and peripheral arteries.
- the inventors also find that P5P is substantially more effective for inhibiting vascular cell proliferation in vivo as compared to vitamin B6.
- the Inventors find that P5P inhibition of vascular cell proliferation can be correlated with lowered incidence of plaque formation and decreased plaque size.
- the inventors show that P5P inhibits vascular cell proliferation, as well as lowers incidences of formation of plaque lesions, and hence would.be effective in treatment of atherosclerosis and/or restenosis.
- P5P is substantially more effective as compared to pyridoxine as a homocysteine lowering agent. Further, the inventors find that pre-atherosclerotic individuals and atherosclerotic individuals treated with P5P have clinically significant reductions in plasma homocysteine levels and lowered incidences of plaque lesions as compared to individuals treated with placebo.
- P5P is substantially more effective in treatment of atherosclerosis and/or restenosis.
- P5P inhibition of apoptosis is related to P5P's ability to antagonize purinergic receptors, and in particular, P2X7 receptors.
- P5P inhibits apoptosis of both cells in vascular walls and cells in plaque lesions.
- the inventors find that the anti- apoptosis properties of P5P appear to be related to its ability to antagonize purinergic receptors.
- P5P is an effective inhibitor of vascular inflammation and that the anti-inflammatory properties of P5P are substantially greater than the anti-inflammatory properties of pyridoxine. While the invention is not limited to any particular theory, it is believed that the effectiveness of P5P in treating and preventing atherosclerosis and restenosis is substantially related to its anti-Inflammatory properties as compared to P5P's lipid lowering properties, homocysteine lowering properties and anti-thrornb ⁇ sis properties. The present inventors find that the anti-inflammatory properties of P5P are also related to its ability to antagonize purinergic receptors.
- the present inventors find that P5P inhibits IL-IQ secretion by monocytes and macrophages which express P2X7 receptors and thereby inhibits inflammation within the vasculature.
- the present inventors further find that P5P is a substantially more effective purinergic receptor antagonist, and consequently anti-inflammatory agent, compared to other vitamin B6 compounds.
- the present inventors find that the antithrombotic properties of P5P contribute to its antianthrogenic properties.
- the present inventors further find that P5P is the more effective antithrombotic agent for use in treating atherosclerosis as compared to vitamin B6.
- the present invention provides a method of treating or preventing atherosclerosis in patient comprising the administration of a therapeutically effective amount of P5P or a pharmaceutically acceptable salt thereof.
- the method of treatment can be used for pre-atherosclerotic individuals.
- Pre- atherosclerotic individuals include those which are risk of developing atherosclerosis (i.e. have one more risk factors such as increased lipids, increased homocysteine, elevated CRP levels) but have only minimal changes to the vasculature (i.e. accumulation of plaque lesions, narrowing of the arteries).
- the administration of pyridoxal-5'- phosphate is useful for preventing the onset of atherosclerosis or delaying the onset of atherosclerosis.
- the method of treatment can also be used with atherosclerotic individuals (i.e. those with clinically significant narrowing of the coronary or peripheral arteries) for retarding the progression of the disease by preventing further damage and by preventing destabilization of existing plaque lesions.
- the invention provides a method of treating atherosclerosis in a patient suffering thereof comprising the administration of a therapeutically effective amount of pyridoxal-5'-phosphate or a pharmaceutically acceptable salt thereof, prior to the patient undergoing a percutaneous coronary intervention.
- This method is useful for atherosclerotic patients for which pharmaceutical intervention alone is insufficient.
- the extent of the disease will be such that the only way to restore adequate blood flow is through surgical intervention such as carotid atherectomy, and in particular through a percutaneous coronary intervention.
- Examples of percutaneous coronary interventions encompassed by the present invention include, but are not limited to: percutaneous transluminal coronary angioplasty (PTCA), rotational atherectomy, directional atherectomy, extraction atherectomy, laser angioplasty, implantation of intracoronary stents and other catheter devices.
- PTCA percutaneous transluminal coronary angioplasty
- rotational atherectomy directional atherectomy
- extraction atherectomy directional atherectomy
- laser angioplasty implantation of intracoronary stents and other catheter devices.
- the patient is administered a therapeutically effective amount of P5P or pharmaceutically acceptable salt thereof, for between 1 and 30 days prior to undergoing the percutaneous coronary intervention and more preferably, 14 days prior to the intervention.
- the method comprises the further step of administering a therapeutically effective amount of P5P or a pharmaceutically acceptable salt thereof, following the percutaneous coronary intervention.
- the duration of post-operative treatment with P5P will depend on a particular patient's need. In some circumstances, long term treatment and even indefinite treatment may be desirable. In other circumstances, short term treatment may be desirable.
- P5P or a pharmaceutically acceptable salt thereof is administered between 1 and 30 days following the percutaneous intervention. In a further preferred embodiment, P5P or a pharmaceutically acceptable salt thereof is administered for at least 30 days following the percutaneous intervention.
- cardioprotective agents which may be administered with P5P or its pharmaceutically acceptable salt include platelet aggregation inhibitors such as: thromboxane A2 inhibitors (e.g. acetylsalicylic acid (ASA)), glycoprotein Ilb/IIIa inhibitors (e.g. abciximab, eptifibatide, tirofiban, lamifiban, xemilofiban, orbofiban, sibrafiban; fradafiban, roxifiban, lotrafiban), adenosine phosphate inhibitors (e.g.
- thromboxane A2 inhibitors e.g. acetylsalicylic acid (ASA)
- glycoprotein Ilb/IIIa inhibitors e.g. abciximab, eptifibatide, tirofiban, lamifiban, xemilofiban, orbofiban, sibrafiban; fradafiban, rox
- clopidogrel dipyridamole, sulfinpyrazone
- fibrinogen- platelet binding inhibitors ticlopidine
- a platelet c ⁇ AMP phosphodiesterase inhibitors such as dipyridamole or cilostazol, or pentoxifylline (trentai).
- the present invention provides a method of treating or preventing vascular inflammation in a patient comprising administering a therapeutically effective amount of a pyridoxal-5'-phosphate or pharmaceutically acceptable salt thereof.
- the patient to be treated may be an individual which is pre-atheroscierotic, and which case, the administration of P5P is particularly useful for not only reducing vascular inflammation but also in reducing the likelihood of developing atherosclerosis.
- the present invention further provides a method of treating or preventing restenosis in a patient suffering thereof or at risk thereof, comprising the administration of a therapeutically effective amount of a pyridoxal-5 1 - phosphate or pharmaceutically acceptable salt thereof.
- the restenosis treated by the methods according to the invention may be the result of a surgical intervention, and in some circumstances a percutaneous coronary intervention, examples of which are discussed above.
- the invention provides a method of treating or preventing bypass graft failure comprising administering to a person in need thereof, a therapeutically effective amount of pyridoxal-5'-phosphate or a pharmaceutically acceptable salt thereof.
- the bypass graft failure may be an artery graft failure, and preferably a coronary artery graft failure.
- the bypass graft failure is a vein graft failure.
- the vein graft failure may be a peripheral or coronary vein graft failure.
- the present invention further provides a method of treating atherosclerosis or restenosis comprising administering to a person in need thereof, a therapeutically effective amount of: (a) pyridoxal-5'-phosphate or a pharmaceutically acceptable salt thereof and (b) an anti-inflammatory agent.
- Anti-inflammatory agents which can be used to practice the invention include but are not limited to: COX-2 inhibitors such as celecoxib, rofecoxib, valdecoxib; pyralones such as phenylbutazone; fenamates such as mefanamic acid, meclofenamate; salicylic acid derivative such as diflunisal; acetic acid derivatives such as diclofenac, indomethacin, sulindac, etodolac, ketorolac, nabumetone, tolemetin; propionic acid derivatives such as ibuprofen, fenoprofen, fluribiprofen, carprofen, ketoprofen, naproxen; tiaprofenic acid, oxaprozin; oxicams such as piroxicam, tenoxicam, meloxicam; biological response modifiers such as anakinra, etanercept, infliximab
- the methods of treatment according to the invention comprise the administration of a therapeutically effective amount of pyr ⁇ doxal-5'-phosphate or a pharmaceutically acceptable salt thereof.
- an “effective amount” or a “therapeutically effective amount” of a pharmacologically active agent is meant a nontoxic but sufficient amount of the drug or agent to provide the desired effect.
- an "effective amount" of one component of the combination is the amount of that compound that is effective to provide the desired effect when used in combination with the other components of the combination.
- the amount that is "effective” will vary from subject to subject, depending on the age and general condition of the individual, the particular active agent or agents, and the like. Thus, it is not always possible to specify an exact “effective amount.” However, an appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
- the therapeutic effective amount of any of the active agents encompassed by the invention will depend on number of factors which will be apparent to those skilled in the art and in light of the disclosure herein. In particular these factors include: the identity of the compounds to be administered, the formulation, the route of administration employed, the patient's gender, age, and weight, and the severity of the condition being treated and the presence of concurrent illness affecting the gastro-intestinal tract, the hepatobiliary system and the renal system. In combination therapies, it may be desirable or effective to give a lower amount of one or more of the compounds administered. Methods for determining dosage and toxicity are well known in the art with studies generally beginning in animals and then in humans if no significant animal toxicity is observed.
- the appropriateness of the dosage can be assessed by monitoring: blood pressure, lipid levels, CRP levels, and homocysteine levels. Where the dose does not improve metabolic, vascular and/or endothelial function or reduce blood pressure following at least 2 to 4 weeks of treatment, the dose can be increased.
- the therapeutically effective amount of P5P is between
- the preferred therapeutically effective amount of P5P is between 0.5 and 50 mg/body weight per day. In a further embodiment of the invention, the preferred therapeutically effective amount of P5P is between 1 and 25 mg/kg body weight per day. In yet another embodiment of the invention, the therapeutically effective amount of P5P is preferably between 1 and 15 mg/kg body weight per day.
- P5P or its pharmaceutically acceptable salt may be administered to a patient in need thereof by any suitable route.
- the methods of treatment of the according to the Invention comprise the oral administration of P5P or a pharmaceutically salt thereof.
- Preferred oral dosage forms contain a therapeutically effective unit dose suitable for a once-daily oral administration.
- the unit dosage for P5P will be between 100, 300, 750 and 1000 mg/day.
- the present invention provides an intravascular stent for in situ delivery of P5P or its pharmaceutically acceptable salt thereof.
- the intravascular stent according to the invention is for use within a narrowed artery and has at least one surface which is reversibly bound with pyridoxal-5'-phosphate or a pharmaceutically acceptable salt thereof.
- the exterior of the stent may be coated with a physiologically compatible matrix adapted for time delayed release of the reversibly bound pyridoxal-5'-phosphate or pharmaceutically acceptable salt thereof upon implantation of the stent within the artery to be treated.
- the intravascular stent is prepared using between 10 mg and 10,000 mg of pyridoxal-5'-phosphate or a pharmaceutically acceptable salt thereof. In another embodiment, the intravascular stent is prepared using between 1000 mg and 10,000 mg of pyridoxal-5'-phosphate or a pharmaceutically acceptable salt thereof. In further embodiment, the intravascular stent is prepared using between 1000 mg and 7,500 mg of pyridoxai-5'-phosphate or a pharmaceutically acceptable salt thereof. In a still further embodiment, the intravascular stent is prepared using between 1000 mg and 5000 mg of pyridoxal-5'-phosphate or a pharmaceutically acceptable salt thereof. In yet a further embodiment, the intravascular stent is prepared using between 10 mg and 1000 mg of pyridoxal-5'-phosphate or a pharmaceutically acceptable salt thereof.
- the intravascular stent according to the invention may be prepared using appropriate prior art methods and materials.
- the construction of intravascular stents for use with narrowed arteries is well known in the art.
- the preparation of intravascular stents adapted for in situ drug delivery is also well known in the art.
- HEK 293 cell line (human), is stabily transfected with the P2X7 receptor [9] to produce HEK 293 P2X7 cells. This cell line does not express any of the other P2X receptors; however it does express P2Y1 and P2Y2 receptors [15].
- Apoptosis - HEK 293 P2X7 (human) cells are treated with ATP and/or BzATP to induce apoptosis (Wen et al., 2003).
- the level of apoptosis is determined using a Cell Death Detection ELISA, which is based on DNA laddering.
- Various doses of P5P are added to the cells to determine its ability to inhibit ATP induced apoptosis.
- OxATP (Murgia et al., 1993), PPADS (Chesseli IP et al., 1998) and/or KN-62 (Humphreys BD et al., 1998) are used as positive controls.
- Membrane Blebbing / Pore Formation - HEK 293 P2X7 (human) cells are treated with ATP and/or BzATP to induce membrane blebbing or pore formation (Virginio C et al (1999) J Physiol 519:335-346. Verhoef PA et al (2003) 3 Immunol 170:5728-5738).
- Membrane blebbing is assessed using YO- PRO 1 (Virginio C et al., 1999. Verhoef PA et al., 2003).
- Various doses of P5P are added to the cells to determine its ability to inhibit ATP induced membrane blebbing.
- OxATP (Murgia et al., 1993), PPADS (Chessell IP et al., 1998) and/or KN-62 (Humphreys BD et al., 1998) are used as positive controls.
- HEK 292 cells P5P treated HEK 293 P2X7 cells resist ATP or BzATP mediated cell apoptosis as compared to untreated HEK 293 P2X7 cells.
- the results show that ATP and BzATP induce ceil apoptosis in P2X7 expressing cells.
- the results further show that P5P inhibits ATP mediated cell apoptosis in P2X7 expressing cells.
- LPS primed THP-I cells are treated with ATP to induced IL-l ⁇ secretion (Grahames CBA et al (1999) Br 3 Pharm 127:1915-1921).
- IL-l ⁇ secretion levels are determined by ELISA.
- Various doses of P5P are added to the cells to determine its ability to inhibit the ATP induced IL-l ⁇ secretion.
- OxATP Grahames et al., 1999
- PPADS Grahames et al., 1999
- KN-62 Grahames et al., 1999
- Results - ATP treatment of LPS primed THP-I cells induces IL- lDDsecretion.
- Treatment of LPS primed THP-I cells with purinergic receptor antagonist OxATP, PPADS or KN-62 inhibits IL-l ⁇ secretion.
- P5P treatment of LPS primed THP-I cells inhibits IL-l ⁇ secretion.
- Example Three - Pyridoxal 5'-phosphate Ameliorates Restenosis in Rabbits Suffering Aortic Ballon Iniurv
- Rabbit Aortic Balloon-Injury Model Forty male New Zealand White rabbits (2.5-3.0 kg) are used. Rabbits are fed regular rabbit chow (control, 20 rabbits) or a 1% cholesterol diet (treated, 20 rabbits) for 8 weeks. Half of each group receives 10 mg/kg P5P (provided by CanAm Bioresearch Inc.) daily by gavage, with the other half receiving saline by gavage.
- P5P Provided by CanAm Bioresearch Inc.
- a 3F Fogarty embolectomy catheter (Baxter) is inserted into the right femoral artery of each rabbit, advanced 25 cm proximally, and then withdrawn to the origin with the balloon inflated to 0.2 mL saline, a step repeated twice (Lau et al., Probucol promotes functional reendothelialization in Walloon-injured rabbit aortas. Circulation, 2003; 107(15) :2031-6).
- the right and left femoral arteries are harvested from each animal (left femoral arteries serve as uninjured controls). Segments for histology are pressure-perfused with formalin, stored in 70% (vol/vol) ethanol, and then embedded in paraffin.
- Histology One 5 qm thick cross-section is taken from each of 6 segments of the femoral aorta and stained with hematoxylin and eosin. Morphometric analysis of the 6 arterial cross-sections per animal is performed using Imagespace software (Molecular Dynamics). The intimal and medial areas of each arterial cross-section specimen is measured, and the average intimal/medial area ratio is determined for each group.
- IL-6 Plasma interleukin-6
- ACE angiotensin-converting enzyme
- HMG-CoA 3-hydroxy-3-methylglutaryl-CoA reductase inhibition
- CRP plasma levels are measured with an immunoassay kit for rabbits (Alpco Diagnostics). Plasma cholesterol levels are measured using colorimetric reactions employing commercial kits (Roche Diagnostics). Homocysteine levels are determined by high performance liquid chromatography, as previously described (Zhloba and Blashko, Liquid chromatographic determination of total homocysteine in blood plasma with photometric detection. 3 Chromatogr B Analyt Technol Biomed Life Sci. 2004; 800(l ⁇ 2):275-80).
- the femoral aorta is located using two- dimensional and color Doppler ultrasound. Image settings are optimized for definition of the endothelial-blood interface. All studies are performed with a vascular 7.5 MHz probe coupled to a Sonos 5500 echograph (Phillips).
- Results - P5P treatment correlates with improved lipid profile, lowered homocysteine levels, lowered CRP levels and improved endothelial function. P5P treatment correlates with decreased incidence of restenosis following PCI.
- PCI percutaneous coronary interventional
- a total of 120 patients are enrolled, with 60 randomized to receive P5P and 60 to receive placebo.
- the primary endpoint is clinical restenosis requiring target lesion revascularization at six months.
- the secondary end points are major adverse cardiac events (MACE) including death, myocardial infarction and revascularization.
- MACE major adverse cardiac events
- Randomization and Drug Regimen - Patients are randomly assigned to receive P5P (provided by CanAm Bioresearch Inc.) 750 mg once day or placebo beginning 14 days before scheduled PCI. P5P or matched placebo is administered as 3 tablets given once daily. All patients will also receive an extra dose of P5P or matched placebos on the evening before PCI, according to random treatment assignment. After PCI, all patients are maintained on their assigned study regimen for 4 additional weeks.
- PCI and follow-Up Evaluation - PCI with or without stent placement and post-PCI management will be performed according to current clinical practice.
- ECGs are obtained before PCI, immediately thereafter, and the morning after PCI.
- Creatine kinase, creatine kinase-MB fraction, and troponin I are measured on the evening after PCI and the following morning.
- Patients are discharged after PCI with 4 weeks of the study medication.
- Aspirin 325 mg/d is given from the time of recruitment and for the entire study duration. All patients treated with stents also receive clopidogrel 75 mg/d for 30 days after PCI. Patients will return at 1 month, 3 months and 6 months for clinical evaluation and drug accountability.
- Patients are assessed for ischemic symptoms and adverse events, whether or not they were related to the study medication or PCI procedure. Blood chemistry values assessed at baseline are measured again at PCI discharge and at follow-up visits. Patients are readmitted for follow-up catheterization and IVUS 5 to 7 months after PCI. Those in whom catheterization is performed for clinical reasons before the fifth month return for repeat IVUS examination at 5 to 7 months if no definite restenosis is present on one dilated site.
- IVUS Examinations and Measurements - IVUS examinations are performed with 30-MHz, 3.2F ultrasound catheters (Tardif et al., Canadian Antioxidant Restenosis Trial (CART-I) Investigators. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation. 2003; 107(4): 552-8). IVUS studies are recorded before PCI whenever possible and are always performed after PCI (after final balloon inflation) and at follow-up (before any subsequent intervention). IVUS is always preceded by an intracoronary injection of nitroglycerin (0.3 mg). All IVUS images are interpreted by experienced technicians supervised by a cardiologist, all of them blinded to treatment assignment. The preintervention, post-PCI, and follow-up studies are analyzed side by side.
- Quantitative Coronary Angiography - Control angiography after PCI and at follow-up are preceded by intracoronary administration of nitroglycerin (0.3 mg). Quantitative analysis is performed to determine dichotomous restenosis rates.
- a PCI segment is defined as restenotic if diameter stenosis is 50% at follow-up, with an increase of 15% in the degree of stenosis compared with the post-PCI angiogram.
- Endothelial Function Blood samples of inflammatory markers, biochemistry, and lipid profile are drawn at hospital admission and again at 1 month, 3 months and 6 months.
- CRP levels are determined by nephelometry, using a high- sensitivity assay (Dade Behring Marburg GmbH), and IL-6 levels will be evaluated by enzyme-linked immunosorbent assay (R&D Systems) (Monakier et al., Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. Chest. 2004; 125(5): 1610-5).
- Homocysteine levels are determined by high performance liquid chromatography, as previously described (Zhloba and Blashko, Liquid chromatographic determination of total homocysteine in blood plasma with photometric detection. 3 Chromatogr B Analyt Technol Biomed Life Sci. 2004; 800(1-2): 275-80).
- Endothelial function is evaluated noninvasively using high- frequency ultrasound of the brachial artery, assessing blood flow response to hyperemia (endothelium-dependent vasodilatation) and nitroglycerin spray (endothelium-independent vasodilatation) (Dupuis et al., Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes.
- Results - P5P treatment correlates with improved lipid profile, lowered homocysteine levels, lowered CRP levels and improved endothelial function. P5P treatment correlates with decreased incidence of restenosis following PCI.
- Kandzari DE Labinaz M, Cantor WJ, Madan M, Gallup DS, Hasseiblad V, Joseph D, Allen A, Green C, Hidinger KG, KFUCoff MW, Christenson RH, Harrington RA, Tcheng JE. Reduction of myocardial ischemic injury following coronary intervention (the MC-I to Eliminate Necrosis and Damage trial). Am J Cardiol 2003; 92(6):660-664.
- Mushett CW Emerson GA. Arteriosclerosis in pyridoxine-deficient monkeys and dogs. Fed Proc 1956; 15:526. 17. Kuzaya F. Experiment on arteriosclerosis and arteriolosclerosis induced in pyridoxine deficient monkeys and their recovery. J Primatol 1962; 3:77.
- Dietary vitamin B6 suppresses colon tumorigenesis, 8-hydroxyguanosine, 4-hydroxynonenal, and inducible nitric oxide synthase protein in azoxymethane-treated mice, J Nutr.Sci Vitaminol (Tokyo) 2002; 48(l):65-68. 48. Slattery ML, Potter JD, Coates A, Ma KN, Berry TD, Duncan DM, Caan BJ. Plant foods and colon cancer: an assessment of specific foods and their related nutrients (United States). Cancer Causes Control 1997; 8(4): 575-590.
- Zahavi M Zahavi 3, Kakkar W. The effect of pyridoxal-5-phosphate on the inhibition of platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation in human platelets. Life Sci 1984; 35(14):1497-1503. -
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05850113A EP1804808A1 (en) | 2004-09-24 | 2005-09-26 | Pyridoxal-5-phosphate and stent for the treatment and prevention of atherosclerosis and restenosis |
US11/575,734 US20080175880A1 (en) | 2004-09-24 | 2005-09-26 | Pyridoxal-5-Phosphate And Stent For The Treatment And Prevention Of Atherosclerosis And Restenosis |
AU2005309352A AU2005309352A1 (en) | 2004-09-24 | 2005-09-26 | Pyridoxal-5-phosphate and stent for the treatment and prevention of atherosclerosis and restenosis |
CA002586421A CA2586421A1 (en) | 2004-09-24 | 2005-09-26 | Pyridoxal-5-phosphate and stent for the treatment and prevention of atherosclerosis and restenosis |
JP2007532740A JP2008514552A (en) | 2004-09-24 | 2005-09-26 | Pyridoxal-5'-phosphate and stent for treating and preventing atherosclerosis and restenosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61271004P | 2004-09-24 | 2004-09-24 | |
US60/612,710 | 2004-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006056038A1 true WO2006056038A1 (en) | 2006-06-01 |
Family
ID=36497688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2005/001471 WO2006056038A1 (en) | 2004-09-24 | 2005-09-26 | Pyridoxal-5-phosphate and stent for the treatment and prevention of atherosclerosis and restenosis |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080175880A1 (en) |
EP (1) | EP1804808A1 (en) |
JP (1) | JP2008514552A (en) |
AU (1) | AU2005309352A1 (en) |
CA (1) | CA2586421A1 (en) |
WO (1) | WO2006056038A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102099049A (en) * | 2008-05-30 | 2011-06-15 | 戴纳米斯制药公司 | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010039992A1 (en) * | 2008-10-01 | 2010-04-08 | The Johns Hopkins University | Platelet function analysis for adverse cardiovascular events |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
WO2001013900A2 (en) * | 1999-08-24 | 2001-03-01 | Medicure International Inc. | Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds |
WO2005060975A1 (en) * | 2003-12-23 | 2005-07-07 | Medicure International Inc. | Combination therapies employing a composition comprising a hmg coa reductase inhibitor and a vitamin b6 related compound |
-
2005
- 2005-09-26 JP JP2007532740A patent/JP2008514552A/en not_active Withdrawn
- 2005-09-26 WO PCT/CA2005/001471 patent/WO2006056038A1/en active Application Filing
- 2005-09-26 EP EP05850113A patent/EP1804808A1/en not_active Withdrawn
- 2005-09-26 CA CA002586421A patent/CA2586421A1/en not_active Abandoned
- 2005-09-26 US US11/575,734 patent/US20080175880A1/en not_active Abandoned
- 2005-09-26 AU AU2005309352A patent/AU2005309352A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
WO2001013900A2 (en) * | 1999-08-24 | 2001-03-01 | Medicure International Inc. | Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds |
WO2005060975A1 (en) * | 2003-12-23 | 2005-07-07 | Medicure International Inc. | Combination therapies employing a composition comprising a hmg coa reductase inhibitor and a vitamin b6 related compound |
Non-Patent Citations (7)
Title |
---|
"Pyridoxal-5-Phosphate Reducing the Risk of Heart Disease and Cancer", VITAMIN RESEARCH PRODUCTS INC., 2001, Retrieved from the Internet <URL:http://intekegen.com/nutrients/pyridoxal5phosphate.htm> * |
FOLSOM ET BAL: "Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study", CIRCULATION, vol. 98, no. 3, 21 July 1998 (1998-07-21), pages 204 - 210 * |
FRISO ET AL: "Low plasma vitamin B-6 concentrations and modulation of coronary artery disease risk", AM. J. CLIN. NUTR., vol. 79, June 2004 (2004-06-01), pages 992 - 998 * |
HATTERSLEY J.: "Vitamin B6: The overlooked key to preventing heart attacks", J. APPL. NUTR., vol. 47, no. 1,2, 1995, pages 24 - 31 * |
ROBINSON ET AL: "Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease", CIRCULATION, vol. 92, no. 10, 15 November 1995 (1995-11-15), pages 2825 - 2830 * |
SELHUB ET AL: "Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis", N.ENGL.J.MED., vol. 332, no. 5, 2 February 1995 (1995-02-02), pages 286 - 291 * |
THORNE RESEARCH INC.: "Monograph: Vitamin B6 (Pyridoxine;Pyridoxal 5'phosphate", ALTERNATIVE MEDICINE REVIEW, vol. 6, no. 1, 2001, pages 87 - 91, Retrieved from the Internet <URL:http://www.thorne.com/pdf/journal/6-1/pyridoxalphos_monograph.pdf> * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102099049A (en) * | 2008-05-30 | 2011-06-15 | 戴纳米斯制药公司 | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
Also Published As
Publication number | Publication date |
---|---|
AU2005309352A1 (en) | 2006-06-01 |
CA2586421A1 (en) | 2006-06-01 |
US20080175880A1 (en) | 2008-07-24 |
EP1804808A1 (en) | 2007-07-11 |
JP2008514552A (en) | 2008-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wöhrle et al. | Comparison of the heparin coated vs the uncoated Jostent®—no influence on restenosis or clinical outcome | |
RU2513153C2 (en) | Device for local and/or regional delivery using liquid formulations of active substances | |
Kunishima et al. | A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation | |
EP1779816B1 (en) | Stent with thin drug-eluting film | |
US8586069B2 (en) | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders | |
RU2481084C2 (en) | Local vascular delivery of probucol, alone or in combination with sirolimus, for treatment of restenosis, vulnerable plaques, aaa (abdominal aorta aneurism) and stroke | |
JP2008504890A (en) | Drug delivery stent formulation for restenosis and vulnerable plaque | |
McGorisk et al. | Endothelial dysfunction in coronary heart disease | |
JP5385785B2 (en) | Medical stent with a combination of melatonin and paclitaxel | |
US9060923B2 (en) | Method of treating vascular disease in diabetic patients | |
Yoon et al. | Local delivery of nitric oxide from an eluting stent to inhibit neointimal thickening in a porcine coronary injury model | |
US20080085293A1 (en) | Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor | |
US20080175880A1 (en) | Pyridoxal-5-Phosphate And Stent For The Treatment And Prevention Of Atherosclerosis And Restenosis | |
JP2005537822A (en) | Use of organic compounds | |
Lin et al. | Heparin-coated balloon-expandable stent reduces intimal hyperplasia in the iliac artery in baboons | |
US6214887B1 (en) | Vascular remodeling agent | |
Cernigliaro et al. | Preventing restenosis after implantation of bare stents with oral rapamycin: a randomized angiographic and intravascular ultrasound study with a 5-year clinical follow-up | |
JP2015535246A (en) | Dual variable region (DVD) immunoglobulin to reduce major adverse cardiovascular events (MACE) in diabetic patients following stenting | |
Kitano et al. | Effect of rivaroxaban and clopidogrel combination therapy on in-stent responses after Everolimus-eluting stent implantation in a porcine coronary model | |
Herdeg et al. | Local catheter-based delivery of antithrombotic or antiproliferative drugs: a new concept for prevention of restenosis | |
Généreux et al. | Double-blind, placebo-controlled evaluation of biorest liposomal alendronate in diabetic patients undergoing PCI: The BLADE-PCI trial | |
EP1839688A1 (en) | Drug-eluting clinical device | |
Kuiper | Early outcome and restenosis after coronary stenting | |
Doven et al. | Angiographic and Clinical Outcome Following Paclitaxel-Eluting Stent (Taxus) Implantation A Single Center Experience | |
Windecker et al. | Interventional cardiology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2586421 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005309352 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 553903 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007532740 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005309352 Country of ref document: AU Date of ref document: 20050926 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005309352 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005850113 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005850113 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11575734 Country of ref document: US |